Skip to main content

Research for undercovered public companies

Company-Sponsored Equity Research

Alliance Equity Research publishes detailed, institutional-quality research on undercovered public companies. We build the financial model alongside the initiation report and update our forecasts as earnings and material developments are reported.

What coverage includes
  1. Initiation report

    Explain the business, industry, forecasts, valuation, and principal risks.

  2. Analyst-built financial model

    Link operating assumptions to the financial statements, funding needs, and valuation.

  3. Continuing coverage

    Cover earnings and major developments, explaining any changes to the estimates.

Why research coverage helps

What investors still need beyond public filings

Financial statements and investor presentations do not always provide the forecasts investors need. For a lightly covered company, readers may have to reconstruct several years of segment results, reconcile adjusted figures to reported earnings, or estimate how new financing affects existing shareholders before they can assess the valuation.

Some questions require specialist analysis. A positive clinical readout does not establish a drug’s commercial prospects or future financing needs. An industrial company may have a strong order backlog but need substantial working capital before those orders generate cash. We examine how such developments affect the forecast and valuation.

A published forecast gives investors assumptions they can test, compare with peers, and revisit after new results. Our guide to the small-cap coverage gap explains where further research can add value.

From company disclosures to investor analysis
  1. Step 1

    Company evidence

    Filings, operating results, sector data and material announcements

  2. Step 2

    Analytical framework

    Operating assumptions, financial forecasts, funding and valuation

  3. Step 3

    Continuing research

    Earnings revisions and event-driven work as the outlook changes

The coverage mandate

Full initiation, financial modeling, and continuing coverage

Our analysts examine the company’s filings, operating history, competitors, and industry before developing forecasts and a valuation. The initiation report explains what drives revenue, earnings, and cash flow, which assumptions most affect valuation, and the principal risks. The financial model shows how those assumptions feed into the estimates.

We agree on the scope with management or investor relations before starting. A recently listed company may need its historical results reconciled. A company entering a new market may need a forecast of the investment required and the returns it could generate. The work depends on the business and the information available.

The initiation serves as a reference for subsequent coverage. Earnings updates and event notes explain how new information affects our estimates. Our research approach describes how we prepare and review that work.

Model-backed analysis

A financial model built around the business

Each model starts with the factors that drive the company’s business. For a biotechnology developer, clinical milestones, eligible patient populations, launch timing, and net pricing can shape the forecast. For a mining company, production schedules, recoveries, capital spending, and commodity prices drive project economics. For technology and industrial businesses, we may focus instead on customer retention, order backlogs, or capacity utilization. We model costs and margins at the level supported by public disclosures.

We connect those assumptions to the income statement, balance sheet, and cash flow forecast. Capital expenditure and working capital are modeled alongside operations. Where funding is important, we estimate cash requirements and the possible effects of debt or new shares. Companies with similar earnings growth can have very different cash needs and outcomes for shareholders.

Valuation follows the forecasts. Depending on the business, we may use discounted cash flow, comparable-company multiples, project net asset value, or risk-adjusted valuation of drug programs. Sensitivities show how individual assumptions affect value, while scenarios test several changes together, such as a construction delay and the additional funding it could require.

Cross-sector expertise

How research changes by industry

The sources and assumptions change with the industry. We examine clinical data, mine plans, equipment orders, software retention, or energy contracts as appropriate, then assess how they affect earnings, cash flow, and financing needs.

Biotechnology and healthcare

Our biotech research evaluates trial design, clinical endpoints, and regulatory timelines. Forecasts account for eligible patients, access, adoption, net pricing, development spending, and program risk. For medical devices, we examine reimbursement, utilization, replacement cycles, and distribution costs.

Metals, mining, and critical minerals

Our mining research connects technical studies to grades, recoveries, payability, and production schedules. We model initial and sustaining capital, operating costs, royalties, and closure obligations, then reconcile project NAV with ownership, financing, corporate costs, and share count.

Semiconductors and technology

Shipment volumes, product mix, capacity, and customer spending drive equipment forecasts. Revenue from servicing installed systems may follow a different cycle from new equipment sales. For software, usage, retention, and contract terms help explain earnings and cash conversion.

Industrials and aerospace

We assess backlog alongside delivery schedules, contract pricing, production constraints, and costs. Forecasts also account for customer advances, inventory needs, capacity investment, and parts and service revenue.

Energy

For producers, we model output, realized prices, hedges, development spending, and reinvestment needs. Infrastructure analysis considers contracts, throughput, counterparty exposure, and expansion capital, distinguishing contracted revenue from market-sensitive earnings.

Continuing coverage

How we cover earnings and major developments

Events that can prompt an update

Earnings releasesFinancing eventsRegulatory milestonesOperating developments

After earnings, we compare reported results with our estimates, review guidance and cash flow, and explain changes to the model. A temporary improvement in product mix may not justify the same forecast revision as sustained volume growth.

Between earnings releases, clinical readouts, permit decisions, financing announcements, and major contracts can change the analysis. We assess financing terms, their effect on the share count, what the funds will pay for, and the execution risks that remain.

The coverage agreement sets out the expected earnings schedule and events that warrant an update. Some call for a focused note; others require revised forecasts. Our research archive shows the different publication formats.

Research reach

Institutional distribution and public access

Public and professional circulation

  • AER research library

    Public initiation reports and a continuing research record

  • Search and AI-assisted discovery

    Searchable research pages that readers can revisit

  • Email and professional channels

    Direct circulation to subscribers and relevant audiences

  • Newswire and financial media

    AER distributes research through newswire and financial media, including Yahoo! Finance.

Institutional research platforms

  • Bloomberg
  • FactSet
  • LSEG
  • AlphaSense
  • ResearchPool
  • Benzinga
  • S&P Capital IQ
  • Morningstar

The platform mix varies by coverage program. Access to reports, financial models, and estimates depends on the platform and subscription.

We agree on the intended distribution as part of the research scope, including which report and model formats are supported by each platform. The AER research library provides a permanent link to the coverage history.

The research team

Research by experienced analysts

CFA charterholdersMBA graduatesChartered Accountant

Our team combines experience in investment research, financial modeling, valuation, and corporate finance. Analysts work from company filings and relevant technical material, documenting the assumptions behind each report and forecast so readers can examine the analysis.

See our analyst profiles for individual backgrounds and published work. We cover listed companies in the United States, Canada, the United Kingdom, Europe, and Australia, with particular attention to businesses receiving limited research coverage.

Editorial independence

The issuer pays. AER controls the research.

Each sponsored publication identifies the company paying for the coverage. Fees are paid in cash for the agreed scope. AER sets the assumptions, valuation, and conclusions. Management may check factual details under the agreed review procedure, but it does not control our analysis. Conclusions can be unfavorable, and our analysts are subject to restrictions on owning or trading covered securities.

We publish valuation analysis and assumptions, but not conventional Buy, Hold, or Sell ratings or price targets. Our research disclosures explain the commercial relationship and editorial policy. Where relevant, distribution is also assessed against EU issuer-sponsored research rules.

Frequently asked questions

Which companies are a good fit for AER coverage?

We focus on undercovered public companies, including small and mid caps and recently listed issuers. We assess the available financial information, existing research, and likely need for updates. Request coverage to discuss your company and its reporting calendar.

Can a company commission coverage if it already has analysts?

Yes. Existing coverage may not examine a business segment, clinical pipeline, or developing asset in enough detail. We identify what further analysis would add before proposing a research program.

How are the scope and fee agreed?

We agree on the initiation report, model, publication schedule, event coverage, and distribution before work begins. Our commercial guide explains what to compare when reviewing research proposals.

How do investors use the report and model?

The report explains the forecasts, valuation assumptions, and main risks. Where available, the associated model allows investors to examine the calculations in more detail. Access to each format depends on the distribution platform and subscription.